共 151 条
[1]
Erickson-Miller CL(2009)Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist Stem Cells 27 424-430
[2]
Delorme E(2009)Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial Lancet 373 641-648
[3]
Tian SS(2011)Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura J Clin Pharmacol 51 842-856
[4]
Hopson CB(2007)Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist Blood 109 4739-4741
[5]
Landis AJ(2017)Eltrombopag added to standard immunosuppression for aplastic anemia N Engl J Med 376 1540-1550
[6]
Valoret EI(2011)Effect of cyclosporine on the pharmacokinetics of aliskiren in healthy subjects J Clin Pharmacol 51 1549-1560
[7]
Sellers TS(2012)Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions J Med Chem 55 4740-4763
[8]
Rosen J(2006)Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan Cancer Chemother Pharmacol 58 374-383
[9]
Miller SG(2010)Eltrombopag does not affect cardiac repolarization: results from a definitive QTc study in healthy subjects Br J Clin Pharmacol 70 24-33
[10]
Luengo JI(2007)Interactions of cyclosporin a with breast cancer resistance protein Drug Metab Dispos 35 576-582